Results 131 to 140 of about 7,921 (224)

Preoperative limbic cortical thinning in mesial temporal lobe epilepsy surgical candidates is associated with pre‐existing and de novo postoperative depression

Epileptic Disorders, Volume 28, Issue 5, Page 1554-1566, October 2026.
Abstract Objective Depression is common in mesial temporal lobe epilepsy (mTLE), but its neuroanatomical basis—and overlap with major depressive disorder (MDD)—remains poorly defined. We investigated whether the cortical and subcortical alterations reported in MDD are also present in mTLE and leveraged the frequent occurrence of depression after ...
Philip Fink‐Jensen, Brice Ozenne, Ane Kloster, Bo Jespersen, Kirsten Vinter, Guido Rubboli, Martin Balslev Jørgensen, Sandor Beniczky, Melanie Ganz, Lars Hageman Pinborg   +9 more
wiley   +1 more source

The identification and characterisation of the target proteins of the anti-epileptic drug R-lacosamide [PDF]

, 2010
(2R)-N-Benzyl-2-acetamido-3-methoxypropionamide (lacosamide) is an anticonvulsant (Choi et al., 1996); under the brand name "Vimpat" this small molecule has recently been approved by the European Medicines Agency and the U.S. Food and Drug Administration
Reamtong, Onrapak, Gaskell, Simon, Eyers, Claire   +2 more
core  

Exploring the efficacy and safety of perampanel in epilepsia partialis continua: A case series

Epileptic Disorders, Volume 28, Issue 5, Page 1669-1674, October 2026.
Abstract Background Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus (SE), which is commonly drug‐resistant requiring treatment with multiple antiseizure medications (ASM). There are no established guidelines for pharmacological management.
Setareh Lahsaee, Kristin M. Ikeda, Stephanie Woodroffe, Benjamin P. Whatley   +3 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, Volume 67, Issue 10, Page 5075-5125, October 2026.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, Volume 67, Issue 10, Page 5042-5074, October 2026.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Study of the relation between the shape of lacosamide crystals and the composition of crystallization medium

, 2016
Crystallization is the critical process used by pharmaceutical industries to achieve the desired size, size distribution, shape and polymorphism of a product material.
Allegaert, Sven
core   +1 more source

New onset refractory status epilepticus (NORSE) versus refractory status epilepticus not meeting NORSE criteria: A comparative clinical and electroencephalography‐based study

Epilepsia, Volume 67, Issue 10, Page 5437-5447, October 2026.
Abstract Objective New onset refractory status epilepticus (NORSE) is a rare, severe presentation of refractory status epilepticus (RSE), with approximately half of cases cryptogenic NORSE (c‐NORSE). We compared electroencephalographic (EEG) findings alongside clinical features between NORSE and RSE not meeting NORSE criteria to better understand ...
Seren Hawksworth, Nina Moutonnet, Gregory Scott, Sanjeev Rajakulendran, Mahinda Yogarajah, Matthew C. Walker, Umesh Vivekananda   +6 more
wiley   +1 more source

Cardiovascular events and mortality in adults with late onset seizures: Focus on enzyme‐modulating antiseizure medications

Epilepsia, Volume 67, Issue 10, Page 5243-5254, October 2026.
Abstract Objective Using a Dutch insurance claims registry, we examine whether people with epilepsy have an increased risk of major ischemic cardiovascular events or death compared to people without epilepsy. We also assess whether this risk differs between users of enzyme‐modulating and non‐enzyme‐modulating antiseizure medications (ASMs).
Paola Vassallo, Nathan A. Shlobin, Mark R. Keezer, Roland D. Thijs, Ley Sander   +4 more
wiley   +1 more source

Intravenous lacosamide for acute repetitive seizures and convulsive status epilepticus in critically ill children

Epilepsia Open
Objective Acute repetitive seizures and convulsive status epilepticus are common neurological emergencies in critically ill children. The aim of the study was to evaluate the effectiveness and safety of intravenous lacosamide in critically ill children ...
Man‐Ru Hsiao, Tzu‐Cheng Tsai, Shao‐Hsuan Hsia, Oi‐Wa Chan, En‐Pei Lee, Jainn‐Jim Lin, Kuang‐Lin Lin   +6 more
doaj   +1 more source

Efficacy of Lacosamide in Patients with Diabetic Neuropathy [PDF]

Journal of Sharif Medical & Dental College
Objective: To compare the efficacy of lacosamide versus placebo in patients with diabetic neuropathy in terms of reduction of the mean pain score. Methodology: This randomized controlled trial (RCT) was conducted at the Department of Medicine, Nishtar ...
Awais Akram, Shahzad Alam Khan, Umair Ahmad   +2 more
doaj